secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001104659-24-114487
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion amends Exscientia acquisition to clarify post-closing board appointments
--------------------------------------------------------------------------------

- Amendment lets Exscientia designate one board member (subject to Recursion board approval) effective at closing; a second member if mutually agreed.
- Supplemental disclosures reveal deal discussions began Oct 2022 with an exploratory 'merger of equals' proposal between CEOs.
- Disclosed Exscientia risk-adjusted revenue forecast: $18M (2024E) rising to $659M (2049E); Recursion revenue forecast $30M (2024E) to $627M (2049E).
- Centerview DCF implied Exscientia equity value $3.90–$6.60 per share; analyst price targets gave implied exchange ratio range of 0.4118x–1.1250x (actual 0.7729x).
- Recursion formed a Transaction Committee in July 2024 to oversee negotiations; no additional compensation or conflicts noted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000110465924114487/0001104659-24-114487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000110465924114487/tm2427472d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-114487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer